Abstract
Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.
MeSH terms
-
Adult
-
Aged
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / pharmacokinetics
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics
-
Chemistry, Pharmaceutical
-
Cohort Studies
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / metabolism
-
Receptors, Vascular Endothelial Growth Factor / administration & dosage*
-
Receptors, Vascular Endothelial Growth Factor / adverse effects*
-
Receptors, Vascular Endothelial Growth Factor / pharmacokinetics
-
Recombinant Fusion Proteins / administration & dosage*
-
Recombinant Fusion Proteins / adverse effects*
-
Recombinant Fusion Proteins / pharmacokinetics
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Recombinant Fusion Proteins
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
aflibercept
-
Receptors, Vascular Endothelial Growth Factor